Dr. Sharman on the Phase III Results of the GENUINE Study in CLL

Jeff Sharman, MD, medical director, Hematology Research, The US Oncology Network, discusses the phase III findings of the GENUINE study, the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).

Jeff Sharman, MD, medical director, Hematology Research, The US Oncology Network, discusses the phase III findings of the GENUINE study, the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).

<<<

View more from the 2017 ASCO Annual Meeting

Related Content:

ASCO Annual MeetingConferenceChronic Lymphocytic Leukemia
Implications of Real-World Data in the 1L Treatment of High-Risk CLL
Navigating Continuous BTKi Therapy for CLL in the 1L Setting
Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer